A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

Archives of General Psychiatry

Volumn 60, Issue 4, 2003, Pages 392-400

  Bowden, Charles L ^a   Calabrese, Joseph R ^b   Sachs, Gary ^c   Yatham, Lakshmi N ^d   Asghar, Shaheen Akthar ^e   Hompland, Magne ^f   Montgomery, Paul ^g   Earl, Nancy ^g   Smoot, Tonya M ^g   DeVeaugh Geiss, Joseph ^g  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f Affective Disorders Clinic   (Norway)

^g GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; PLACEBO; PSYCHOTROPIC AGENT; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR I DISORDER; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPOMANIA; INFECTION; INFLUENZA; INSOMNIA; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MANIA; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RAPID CYCLING BIPOLAR DISORDER; RASH; RECURRENT DISEASE; RELAPSE; SOMNOLENCE;

EID: 0037385145     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.60.4.392     Document Type: Article

References (43)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry. 1994;51:8-19.
2. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 1998;50:143-151.
3. Szadoczky E, Papp Z, Vitrai J, Rihmer Z, Furedi J. The prevalence of major depressive and bipolar disorders in Hungary. J Affect Disord. 1998;50:153-162.
4. Schou M. The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians. J Affect Disord. 1998;50:253-259.
5. Simpson SG, Jamison KR. The risk of suicide in patients with bipolar disorders. J Clin Psychiatry. 1999;60(suppl 2):53-56.
6. Hopkins HS, Gelenberg AJ. Treatment of bipolar disorder: how far have we come? Psychopharm Bull. 1994;30:27-38.
7. Cusin C, Serretti A, Lattuada E, Mandelli L, Smeraldi E. Impact of clinical variables on illness time course in mood disorders. Psychiatry Res. 2000;97:217-227.
8. Kessing LV, Andersen PK, Mortensen PB, Bolwig TG. Recurrence in affective disorder, I: case register study. Br J Psychiatry. 1998;172:23-28.
9. Bowden CL, Lecrubier Y, Bauer M, Goodwin G, Greil W, Sachs G, von Knorring L. Maintenance therapies for classic and other forms of bipolar disorder. J Affect Disord. 2000;59(suppl 1):S57-S67.
10. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry. 1997;58:470-478.
11. Harrow M, Goldberg JF, Grossman LS, Meltzer HY. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry. 1990;47:665-671.
12. O'Connell RA, Mayo JA, Flatow, Cuthbertson B, O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry. 1991;159:123-129.
13. Keck PE, McElroy SL. Outcome in the pharmacologic treatment of bipolar disorder. J Clin Psychopharmacol. 1996;16(suppl 1):15S-23S.
14. Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev [serial online]. 2001;2:CD003013. Available at: http://www.update-software.com/abstracts/ab003013.htm. Accessed March 19, 2002. Fee required.
15. Carabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999;60:79-88.
16. Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in bipolar rapid cycling [letter]. Am J Psychiatry. 1996;153:1236.
17. Fatemi SH, Rapport DJ, Calabrese JR, Thuras P. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry. 1997;58:522-527.
18. Fogelson DL, Sternbach H. Lamotrigine treatment of refractory bipolar disorder. J Clin Psychiatry. 1997;58:271-273.
19. Kusumakar V, Yatham LN. Lamotrigine treatment of rapid cycling bipolar disorder. Am J Psychiatry. 1997;154:1171-1172
20. Mauri MC, Laini V, Somaschini E, Ami A, Giannelli A, Sostero M. Lamotrigine: an alternative drug in the prophylaxis of bipolar disorder [abstract]. Eur Neuropsychopharmacol. 1997;6:S161.
21. Sporn J, Sachs GS. The anticonvulsant lamotrigine in treatment-resistant manicdepressive illness. J Clin Psychopharmacol. 1997;17:185-189.
22. Walden J, Hesslinger B, van Calker D, Berger M. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry. 1996;29:193-195.
23. Calabrese JR, Suppers T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry. 2000;61:841-850.
24. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Ocatelli G, Leverich GS, Post RM. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20:607-614.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
27. Endicott J, Spitzer RI. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry. 1978;35:837-844.
28. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: National Institute of Mental Health; 1976:218-222. US Dept of Health, Education, and Welfare publication (ADM) 76-338.
29. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale. Arch Gen Psychiatry. 1976;33:766-771.
30. Zerjac-Lacombe S, Tabarsi E. Lamotrigine: a review of clinical studies in bipolar disorders. Can J Psychiatry. 2001;46:328-333
31. Sachs GL, Koslow CL, Ghaemi SN. The treatment of bipolar depression. Bipolar Disorders. 2000;2:256-260.
32. Bowden CL, Calabrese JR, McElroy S, Gyulai L, Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57:481-489.
33. Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders, V: a double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry. 1976;33:117-120.
34. Denicoff KD, Smith-Jackson EE, Disney ER, Suddath RL, Leverich GS, Post RM. Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p). J Clin Psychiatry. 1997;58:470-478.
35. Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Muller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomised study. J Affect Disord. 1997;43:151-161.
36. Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol. 1998;18:455-460.
37. Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol. 1999;14:277-281.
38. Hirschfeld R, Weisler R, Keck P Jr, Ahern E, Revicki D. Cost-effectiveness evaluation of divalproex sodium vs lithium in the treatment of bipolar disorder [abstract]. In: Proceedings of the Annual Meeting of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1999.
39. Maj M. Lithium prophylaxis of bipolar disorder in ordinary clinical conditions: patterns of long-term outcome P 21. In: Goldberg JF, Harrow M, eds. Bipolar Disorders, Clinical Course and Outcome. Arlington, Va: American Psychiatric Press Inc;1999:21-38.
40. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry. 1996;153:993-1000.
41. Bouman TK, Niemantsverdriet-van Kampen JG, Ormel J, Slooff CJ. The effectiveness of lithium prophylaxis in bipolar and unipolar depressions and schizo-affective disorders. J Affect Disord. 1986;11:275-280.
42. Maj M, Pirozzi R, Magliano L. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors. Am J Psychiatry. 1995;152:1810-1811.
43. Baldessarini RJ, Tohen M, Tondo L. Maintenance treatment in bipolar disorder. Arch Gen Psychiatry. 2000;57:490-492.